JPMorgan Predicted Strong Wegovy Pill Sales (and Was Right). Is Novo Nordisk Stock a Buy Now?

JPMorgan Predicted Strong Wegovy Pill Sales (and Was Right). Is Novo Nordisk Stock a Buy Now?

Novo Nordisk lived up to expectations for its Wegovy pill in the third quarter, but it still has more work ahead.

Novo Nordisk's (NYSE: NVO) 70% Stock Decline Creates Value Case As Wegovy Pill Crosses 8 Million Prescriptions

Shares of Novo Nordisk (NYSE: NVO) have shed roughly 70% of their value since a 2024 peak, drawing fresh attention from income and value-oriented investors watching the drugmaker’s latest earnings. The company’s third-quarter results showed operating profit falling 9% year over year, a decline that reflects a deliberate strategic shift rather than deteriorating demand. Novo […]